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Objective: To explore the antiviral activity of antibiotic compounds, mainly amino-
glycosides and tetracyclines against Japanese encephalitis virus (JEV) induced infection
in vitro.
Methods: Antiviral activity were evaluated against JEV using cytopathic effect inhibi-
tion assay, virus yield reduction assay, caspase 3 level, extracellular viral detection by
antigen capture ELISA and viral RNA levels.
Results: JEV induced cytopathic effect along with reduction of viral progeny plaque
formation indicated antiviral potential of the compounds suggesting that antibiotics had
broad spectrum activity. Doxycycline and kanamycin administration in dose dependent
manner declined viral RNA replication.
Conclusions: The present study shows kanamycin and doxycycline can affect virion
structure and alter replication causing inhibition of JEV induced pathogenesis in vitro.1. Introduction
Japanese encephalitis (JE) is an arboviral neurologic disease
of global public health importance. The disease is endemic in
many parts of South Asia, Southeast Asia, East Asia and the
Paciﬁc. Most of JE disease is asymptomatic with no apparent
illness. The ratio of asymptomatic to symptomatic infection
varies between 25:1 and 1000:1 [1]. Case fatality rate among
symptomatic patients is 25%–30%, with neuropsychiatric
sequelae evident in 30%–50% of survivors [2]. Annually,
approximately 30000–50000 JE cases, including 10000
deaths are reported [3]. JE is caused by a positive sense RNA
virus–Japanese encephalitis virus (JEV), a member of JEV
serocomplex of genus Flavivirus under family Flaviviridae.
JEV is transmitted in humans mainly by Culex species of
mosquitoes [4]. The treatment therapy for JE is mainly
conservative and supportive.
Recently, tetracyclines and aminoglycosides speciﬁcally 2
deoxy streptamine (2 DOS) aminoglycoside derivative com-
pounds have been successfully proved beneﬁcial against viralinfection namely dengue virus, West Nile virus and reovirus [5–
7]. We report the efﬁciency of doxycycline and kanamycin
against JEV induced infection in an in vitro pharmacokinetic
model system.
2. Materials and methods
2.1. Biosafety statement
All infectious work with JEV was performed in a high
containment facility at Arbovirology Laboratory, Regional
Medical Research Centre (RMRC), Northeast Region, Indian
Council of Medical Research, India. The present work was done
under the Senior Research Fellowship scheme awarded by In-
dian Council of Medical Research, India.
2.2. Cell line, drugs and virus
Baby hamster kidney (BHK-21), a ﬁbroblast cell line was
procured from National Cell Centre for Sciences, Pune, India
and maintained at RMRC, Northeast Region. The cell line was
being maintained in minimum essential medium (MEM) sup-
plemented with 10% fetal bovine serum and 5% tryptose
phosphate broth. Eight drugs were used in the present study:
brefeldin A, chlortetracycline, demeclocycline, doxycycline,
gentamicin, kanamycin, rolitetracycline and tetracycline.ess article under the CC BY-NC-ND license
Table 1
CC50, IC50 and TI dose of candidate compounds.
Candidate compound CC50 (mg/mL) IC50 (mg/mL) TI
Brefeldin A 10 ± 2 – –
Chlortetracycline 189 ± 8 50 ± 7 4.0
Demeclocycline 9 ± 2 – –
Doxycycline 95 ± 6 22 ± 1.2 4.3
Gentamicin 109 ± 12 53 ± 9 2.0
Kanamycin 381 ± 139 70 ± 15 5.4
Rolitetracycline 300 ± 77 76 ± 25 4.0
Tetracycline 303 ± 139 74 ± 33 4.0
Standard
Minocycline 342 ± 17 34 ± 9 10.0
Ribavirin 195 ± 4 20 ± 2 10.0
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ocycline, a second generation tetracycline compound were used
as control drugs. JEV strain P20778 (GenBank accession no.
AF080251, source: human, year: 1958, place: Vellore, India)
was obtained from National Institute of Virology, Pune, India
and propagated in BHK-21 cell line.
2.3. Cytotoxicity of antibiotics and standards
Initially, cytotoxic concentration at 50% end point (CC50) for
the drugs were determined by 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT) assay [8,9]. Brieﬂy, a 96
well plate (made by Genaxy) was pre-seeded with 3.5 × 105
cells/mL overnight. Next day, the MEM was discarded and
replaced with respective dose concentration of drugs starting
from 0 mg/mL to 520 mg/mL prepared in MEM. In control wells,
plain MEM was added and allowed to incubate for 72 h (37 C,
5% CO2). After incubation, MTT reagent was added under dark
conditions. Plate was again incubated for 4 h. After this, MTT
solvent solution was added and incubated overnight. Following
day, the reading of the plate was taken at 490 nm in an ELISA
reader [10]. The optical density reading of the drugs at different
concentrations was plotted. The concentration of compound
reducing cell viability by 50% (CC50) was determined from a
curve relating percent cell viability to the concentration of
compounds.
2.4. Screening for virus induced cytopathic effect
inhibition (CPEI)
Since the two drugs, brefeldin A and demeclocycline,
showed high cytotoxicity at very low doses, subsequent exper-
iments were carried out with remaining drugs. Antiviral activity
assay of drugs against JEV strain P20778 were screened using
CPEI assay in a 96 well plate [8].
2.5. Conﬁrmation of antiviral activity by virus yield
reduction assay
The drug susceptibility was evaluated by virus yield
reduction assay. Cells were pre-treated with different concen-
trations of drugs (0–100 mg/mL) for 24 h prior to infection.
BHK 21 cells were inoculated with JEV strain P20778 at a
multiplicity of infection of 0.1. Following a 1 h virus incuba-
tion period, the medium was removed and infected cultures
were incubated with medium containing respective concentra-
tions of drugs. At 48 h post-infection cultures were deep-frozen
at −80 C. After thawing of the cultures, infectious virus titres
were determined for progeny virus yields by standard plaque
titrations. All the experiments were run in triplicates. Percent-
age inhibitions of plaques were determined using the following
formula:
% Inhibition = (Number of plaques in virus control − Number of
plaques in drug treated)/(Number of plaques in virus
control) × 100
The antiviral activity was expressed as 50% inhibitory con-
centration (IC50) of the compound, i.e. concentration of the
compound required to inhibit viral plaques by 50% as compared
to virus control [6,8,11].2.6. Extracellular antigen detection by Ag capture
ELISA
An Ag capture ELISA was standardized to detect presence of
antigens based on Gajanana et al., 1995 with modiﬁcations [12].
2.7. Infectious virus yield inhibition by TCID50/mL
The supernatant ﬂuid was used to determine virus yield based
on Reed and Munch method [13].
2.8. Caspase 3 assay: indicators of apoptosis activation
Caspase 3 of the samples was evaluated by using Caspase 3
Assay Kit, Colorimetric (made by Sigma–Aldrich company)
according to manufacturer's instructions.
2.9. Monitoring of JEV RNA loads
JEV RNA was monitored using primers: F 50-GGGAGT-
GATGGCCCCTGCAAAATT-30 and R 50-TCCAATGGAGC-
CAAAGTCCCAGGC-30 [14]. The speciﬁcity of the amplicon
was veriﬁed by melt curve analysis. Viral RNA load in
antibiotics treated cells was compared to untreated controls
and was normalized to the reference gene (b-actin). b-Actin
gene primers for BHK-21 were: 50-ACTGGCATTGTGATG-
GACTC-30 and 50-CATGAGGTAGTCTGTCAGGTC-30 [15].
Data was expressed as relative fold expression to untreated
controls, which was deﬁned as 1.0 fold (100%). Triplicate
reactions were carried out for each sample and no template
control was included as a negative control.
2.10. Statistical analysis
Statistical analysis was done with the help of SPSS v.16
software. CC50 and IC50 values were calculated using means
with standard deviations (SD). An unpaired student's t test was
used for comparisons between 2 groups. One way ANOVA test
was used to determine signiﬁcance among the groups. Value of
P < 0.05 was considered signiﬁcant.
3. Results
3.1. Antiviral screening of drug efﬁcacy
Initially, CC50 of all 10 drugs were determined (Table 1). Out
of all drugs, both brefeldin A and demeclocycline showed
Figure 2. Virus reduction assay for drug chlortetracycline determining
IC50 of chlortetracycline.
Figure 3. Extracellular viral antigen post treatment with candidate drug comp
Figure 4. Progeny virus yield post treatment with candidate drug compounds.
Figure 1. CPEI assay of doxycycline against P20778 strain.
A: virus + drug doxycycline treated cells; B: virus treated cells; C: cell control.
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drugs were excluded from further experiments. BHK-21 cell line
was used to study JEV induced pathogenicity due to their sus-
ceptibility to JEV entry and replication. The effect of the
experimental drugs upon in vitro JEV induced infection was
screened. The antiviral activity of the drugs was initially eval-
uated using CPEI assay. JEV infected BHK-21 cell line
exhibited a typical cytopathic effect (CPE) with detached
rounded cell bodies. It was observed that all 8 drugs hadounds.
Figure 5. Caspase 3 levels at 48 h post infection and treatment with candidate compounds.exhibited JEV induced CPE reduction in a concentration
dependent manner (Figure 1). The compounds subjected to virus
yield reduction showed a dose dependent reduction of plaques
formed by JEV strain P20778 with an IC50 value of kanamycin,
chlortetracycline (Figure 2) and doxycycline of (70 ± 15) mg/
mL, (50 ± 7) mg/mL and (22 ± 1.2) mg/mL respectively
(Table 1). The speciﬁcity of antiviral compound was determined
by calculating therapeutic index (TI), which was a ratio of CC50
to IC50 (Table 1). Kanamycin (TI: 5.4), doxycycline (TI: 4.3)
and chlortetracycline (TI: 4) showed moderate activity against
JEV compared to the two standards. The standards, minocycline
and ribavirin exhibited high TI. Therefore, subsequent experi-
ments were carried out with kanamycin, chlortetracycline and
doxycycline.
3.2. Kinetics of antiviral activity of drugs against viral
antigen and viral progeny yield
The antiviral activity of drugs was evaluated by presence
of viral antigen (P < 0.05) (Figure 3) and inhibition of virus
yield (P < 0.05) (Figure 4). It was seen that doxycycline and
kanamycin showed decline of soluble JEV antigen and in-
fectious virus yield progeny on dose dependent manner.
3.3. Drug inhibition on JEV induced caspase 3 activated
apoptosis pathway
It was observed that chlortetracycline, doxycycline and
kanamycin did not have any effect on extracellular caspase 3
protein reduction (P < 0.05) (Figure 5).
3.4. JEV viral RNA inhibition monitored by qPCR
Viral RNA was inhibited at concentration dependent manner.
Doxycycline (5–40 mg/mL), kanamycin (5–50 mg/mL) and
chlortetracycline (10–50 mg/mL) showed viral RNA inhibition at
varied drug concentration range. Standard minocycline showed
viral RNA inhibition at 20–50 mg/mL dose concentration
(Figure 6).Figure 6. Expression ratio at concentrations (5–50 mg/mL) of candidate
drug compounds.
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This study is set to identify synthetic compounds belonging
to tetracyclines and 2 DOS aminoglycosides groups as effective
therapeutic agents against JEV in an in vitro system. Antibiotics
are effective against bacterial microbes with the main target sites
include: the decoding (or A-site) on the 30S, the peptidyl
transferase center on the 50S, and the peptide exit tunnel on the
50S of ribosomes [16]. However, in recent years, certain broad
spectrum antibiotics having protein synthesis inhibition mode
of action, have also been found to be effective against viral
etiologies [17,18]. In vitro susceptibility of viruses to antiviral
agents is often assessed on ability to lower virus induced CPE
[8]. Inhibition of JEV induced CPE suggests that antibiotics
have broad spectrum activity. In the present study, antiviral
effect of antibiotics, as witnessed in the virus yield reduction
assay with reduction of viral progeny plaque formation, was
another pointer of antiviral potential of the compounds.
However, IC50 values of these three drugs were relatively higher
but they all fell within the range of optimum drug concentration
recommended for use in cell culture [19,20]. Antiviral activity
against JEV was exhibited by kanamycin, doxycycline and
chlortetracycline with TI values of 5.4, 4.3 and 4.0 respectively.
We demonstrated that treatment of cells with antibiotics greatly
reduced yield of JEV at sub-cytotoxic dose. Thus, we can state
that the effects of drugs were in direct action with the virus and not
affecting the host cell membrane.
JEV induces apoptosis of infected cells. Caspase 3, the
executor molecule of apoptotic signaling pathway is activated in
late stage of cell death programme. However, the drugs were
unable to restrict the caspase 3 level, thus showing no role in
inhibition of extracellular caspase 3 protein molecules.
Viral progeny decreased as evidenced by plaque assay,
showed that the drugs inhibited JEV replication in the cell line.
Drugs at dose dependent manner declined viral RNA replication,
especially doxycycline and kanamycin, which showed similar
results with standard drug, minocycline [21]. Both the drugs,
doxycycline and kanamycin exhibited signiﬁcant decline in
viral RNA load in the drug treated cells. In vitro ﬁndings are
also supported by the in silico study, where, virtual screening
of JEV NS3 helicase/NTPase and candidate drugs (mainly
kanamycin and doxycycline) showed favorable interactions in
motifs I, II and VI of helicase suggesting possible viral
replication inhibition (RMRC unpublished data).
Kanamycin belongs to 2 DOS aminoglycosides antibiotics
compounds. 2-DOS contains a rigid framework of hydrogen
bond donors among which the rigid cis-1, 3 arrangements of
amino groups is responsible for selective interaction with
structural motifs in RNA targets. The primary site of mode of
action of 2 DOS aminoglycosides is 30S of bacterial ribosomes.
Recently, other sites of drug action have been discovered, which
are self splicing group I introns, hammerhead ribozyme, hepa-
titis delta ribozyme, RNAse P and transfer RNA. Multiple
aminoglycosides binding sites have been reported on both small
and large RNA molecules. Aminoglycosides have also shown to
bind to hepatitis viral RNA, blocking formation of RNA-peptide
and RNA-protein complex. 2 DOS aminoglycosides are poten-
tial viral RNA binding molecules in case of human immuno-
deﬁciency virus which is a single stranded positive sense
enveloped virus. There aremultiple RNA–RNA andRNA-protein
interactions in human immunodeﬁciency virus life cycle, some of
which may serve as potential targets for aminoglycosides basedtherapeutics based on aminoglycoside scaffolds. Therefore, it can
be stated that aminoglycosides are rather universal binders which
binds to different RNA targets. The possible mode of interaction
may be the electrostatic interactions between RNA and amino-
glycoside moieties which probably cause ‘structural electrostatic
complementarities’ [17]. This mechanism probably explains the
ability of kanamycin acting against JEV, also a single stranded
positive sense RNA virus.
Polycyclic naphthacene carboxamide derived compounds or
more commonly known as the tetracycline group of compounds
are protein synthesis inhibitor molecules acting on bacterial
microbes. There are numerous non bacterial uses of tetracycline
compounds. Hydroxyl groups in tetracycline rigid skeleton are a
source of radical oxygen species that irreversibly damage mac-
romolecules such as DNA, RNA and proteins. These effects lead
in cellular death for oxidative stress. The compounds alter bal-
ance equilibrium sequestering divalent ions (ex-Ca2+) much
more than the monovalent ions (ex-K+) in eukaryotic cells.
Tetracycline forms complexes with Ca2+ and K+ ions present in
blood plasma. Highly lipophilic tetracycline compound like
doxycycline exhibits bactericidal mechanism, which causes
membrane damage (as ionophores) [18]. Another compound
chlortetracycline is a potent and speciﬁed Ca2+ ionophore [22].
Therefore, tetracyclines have been recently identiﬁed as a
family containing chemically diverse mechanisms of activity
which interacts with multiple targets.
Thus, we can state that tetracyclines and aminoglycoside
compounds have diverse mode of action against non conventional
targetmicrobes.Wehave found in our present study the efﬁcacy of
kanamycin, a 2 DOS aminoglycoside and doxycycline, a second
generation tetracycline compound affecting virion structure and
altering replication causing inhibition of JEV induced pathogen-
esis in an in vitro pharmacokinetic model system.Conﬂict of interest statement
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